LIFEVANTAGE CORP Lease, Cost
LIFEVANTAGE CORP (LFVN) reported Lease, Cost of $1.87 million for the 12-month period ending 2026-06-30, per its 10-K filed 2026-08-27.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:LeaseCost · last filed 2026-08-27
- LIFEVANTAGE CORP lease, cost for the quarter ending 2026-06-30 was $462.00K, a 9.77% decline year-over-year.
- LIFEVANTAGE CORP lease, cost for the quarter ending 2026-03-31 was $463.00K, a 9.75% decline year-over-year.
- LIFEVANTAGE CORP lease, cost for the quarter ending 2025-12-31 was $469.00K, a 7.13% decline year-over-year.
- LIFEVANTAGE CORP lease, cost for the quarter ending 2025-09-30 was $474.00K, a 8.14% decline year-over-year.
- LIFEVANTAGE CORP lease, cost for fiscal 2026 was $1.87M, a 8.75% decline from fiscal 2025.
- LIFEVANTAGE CORP lease, cost for fiscal 2025 was $2.05M, a 4.12% decline from fiscal 2024.
- LIFEVANTAGE CORP lease, cost for fiscal 2024 was $2.13M, a 26.31% decline from fiscal 2023.
- LIFEVANTAGE CORP lease, cost for fiscal 2023 was $2.90M, a 10.84% decline from fiscal 2022.
| Period end | Lease, Cost 3 month | Lease, Cost 6 month | Lease, Cost 9 month | Lease, Cost 12 month |
|---|---|---|---|---|
| 2026-06-30 | $462.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-08-27 | $925.00K derived: sum of 2 quarters · filed 2026-08-27 | $1.39M derived: sum of 3 quarters · filed 2026-08-27 | $1.87M 10-K · filed 2026-08-27 |
| 2026-03-31 | $463.00K 10-Q · filed 2026-05-06 | $932.00K derived: sum of 2 quarters · filed 2026-05-06 | $1.41M 10-Q · filed 2026-05-06 | $1.92M derived: sum of 4 quarters · filed 2026-08-27 |
| 2025-12-31 | $469.00K 10-Q · filed 2026-02-04 | $942.00K 10-Q · filed 2026-02-04 | $1.46M derived: sum of 3 quarters · filed 2026-08-27 | $1.97M derived: sum of 4 quarters · filed 2026-08-27 |
| 2025-09-30 | $474.00K 10-Q · filed 2025-11-04 | $986.00K derived: sum of 2 quarters · filed 2026-08-27 | $1.50M derived: sum of 3 quarters · filed 2026-08-27 | $2.00M derived: sum of 4 quarters · filed 2026-08-27 |
| 2025-06-30 | $512.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-08-27 | $1.02M derived: sum of 2 quarters · filed 2026-08-27 | $1.53M derived: sum of 3 quarters · filed 2026-08-27 | $2.05M 10-K · filed 2026-08-27 |
| 2025-03-31 | $513.00K 10-Q · filed 2026-05-06 | $1.02M derived: sum of 2 quarters · filed 2026-05-06 | $1.53M 10-Q · filed 2026-05-06 | $2.05M derived: sum of 4 quarters · filed 2026-05-06 |
| 2024-12-31 | $505.00K 10-Q · filed 2026-02-04 | $1.02M 10-Q · filed 2026-02-04 | $1.53M derived: sum of 3 quarters · filed 2026-02-04 | $2.05M derived: sum of 4 quarters · filed 2026-02-04 |
| 2024-09-30 | $516.00K 10-Q · filed 2025-11-04 | $1.03M derived: sum of 2 quarters · filed 2025-11-04 | $1.54M derived: sum of 3 quarters · filed 2025-11-04 | $2.06M derived: sum of 4 quarters · filed 2025-11-04 |
| 2024-06-30 | $512.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-09-04 | $1.02M derived: sum of 2 quarters · filed 2025-09-04 | $1.54M derived: sum of 3 quarters · filed 2025-09-04 | $2.13M 10-K · filed 2025-09-04 |
| 2024-03-31 | $513.00K 10-Q · filed 2025-05-06 | $1.03M derived: sum of 2 quarters · filed 2025-05-06 | $1.62M 10-Q · filed 2025-05-06 | $2.34M derived: sum of 4 quarters · filed 2025-05-06 |
| 2023-12-31 | $519.00K 10-Q · filed 2025-02-05 | $1.11M 10-Q · filed 2025-02-05 | $1.82M derived: sum of 3 quarters · filed 2025-02-05 | $2.46M derived: sum of 4 quarters · filed 2025-02-05 |
| 2023-09-30 | $590.00K 10-Q · filed 2024-10-29 | $1.30M derived: sum of 2 quarters · filed 2024-10-29 | $1.94M derived: sum of 3 quarters · filed 2024-10-29 | $2.76M derived: sum of 4 quarters · filed 2024-10-29 |
| 2023-06-30 | $715.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-08-28 | $1.35M derived: sum of 2 quarters · filed 2024-08-28 | $2.17M derived: sum of 3 quarters · filed 2024-08-28 | $2.90M 10-K · filed 2024-08-28 |
| 2023-03-31 | $637.00K 10-Q · filed 2024-05-02 | $1.46M derived: sum of 2 quarters · filed 2024-05-02 | $2.18M 10-Q · filed 2024-05-02 | |
| 2022-12-31 | $822.00K 10-Q · filed 2024-01-30 | $1.54M 10-Q · filed 2024-01-30 | ||
| 2022-09-30 | $721.00K 10-Q · filed 2023-11-09 | |||
| 2022-06-30 | $3.25M 10-K · filed 2023-08-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Adicet Bio, Inc. (ACET) | United States | $0.078B | -0.81 |
| Valion Bio, Inc. (VBIO) | United States | $0.077B | |
| MAIA Biotechnology, Inc. (MAIA) | United States | $0.077B | -2.30 |
| iBio, Inc. (IBIO) | United States | $0.077B | -2.94 |
| Verrica Pharmaceuticals Inc. (VRCA) | United States | $0.076B | -3.39 |
| OS Therapies Inc (OSTX) | United States | $0.076B | -2.17 |
| Gain Therapeutics, Inc. (GANX) | United States | $0.080B | -4.40 |
| Aldeyra Therapeutics, Inc. (ALDX) | United States | $0.074B | -5.57 |
| Cingulate Inc. (CING) | United States | $0.073B | -2.64 |
| Spero Therapeutics, Inc. (SPRO) | United States | $0.073B | 17.41 |